Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SICHUAN KELUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 28.29 CNY | +1.33% | -1.36% | +6.31% | |
| Sales 2023 * | 21.54B 3.01B | Sales 2024 * | 23.12B 3.23B | Capitalization | 41.65B 5.81B |
|---|---|---|---|---|---|
| Net income 2023 * | 2.33B 325M | Net income 2024 * | 2.6B 363M | EV / Sales 2023 * | 2,12x |
| Net Debt 2023 * | 3.93B 549M | Net Debt 2024 * | 1.36B 190M | EV / Sales 2024 * | 1,86x |
| P/E ratio 2023 * | 17,8x | P/E ratio 2024 * | 16,0x | Employees | 18,422 |
| Yield 2023 * | 3,11% | Yield 2024 * | 2,26% | Free-Float | 64.03% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.33% | ||
| 1 week | -1.36% | ||
| Current month | -1.36% | ||
| 1 month | +1.14% | ||
| 3 months | +9.19% | ||
| 6 months | -5.26% | ||
| Current year | +6.31% |
1 week
27.43
28.78
1 month
26.6629.20
Current year
24.3533.28
1 year
21.6933.28
3 years
14.5333.28
5 years
14.5333.50
10 years
12.2636.07
| Managers | Title | Age | Since |
|---|---|---|---|
Si Chuan Liu
CEO | Chief Executive Officer | 39 | 2009 |
Ge Xin Liu
FOU | Founder | 72 | 1995 |
De Gui Lai
DFI | Director of Finance/CFO | 51 | 2000 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
FOU | Founder | 72 | 1995 |
Guang Ji Wang
BRD | Director/Board Member | 70 | 2018 |
Yun Pei Guo
BRD | Director/Board Member | 76 | 2016 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.84% | 2 M€ | -15.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 28.29 | +1.33% | 12,578,060 |
| 23-12-07 | 27.92 | -0.64% | 7,064,082 |
| 23-12-06 | 28.1 | +0.54% | 11,578,710 |
| 23-12-05 | 27.95 | -0.18% | 8,681,488 |
| 23-12-04 | 28 | -1.48% | 8,946,525 |
End-of-day quote Shenzhen Stock Exchange, December 07, 2023
More quotes
Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows:
- manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.);
- other (2%).
China accounts for 94.6% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
28.29CNY
Average target price
38.25CNY
Spread / Average Target
+35.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.31% | 5 753 M $ | |
| +63.47% | 529 B $ | |
| +42.56% | 430 B $ | |
| -12.58% | 374 B $ | |
| -6.49% | 263 B $ | |
| -7.63% | 261 B $ | |
| +1.35% | 198 B $ | |
| -9.77% | 197 B $ | |
| -43.83% | 162 B $ | |
| +2.47% | 145 B $ |
